Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Time to clinical improvem.. 64% primary Improvement Relative Risk Clinical improvement 90% Mild pneumonia 43% Viral clearance -4% Favipiravir  Sirijatuphat et al.  EARLY TREATMENT  RCT Is early treatment with favipiravir beneficial for COVID-19? RCT 93 patients in Thailand (December 2020 - July 2021) Faster improvement with favipiravir (p=0.00046) c19early.org Sirijatuphat et al., medRxiv, June 2022 Favors favipiravir Favors control

Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study

Sirijatuphat et al., medRxiv, doi:10.1101/2022.06.06.22275902, TCTR20200514001
Jun 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 93 patients in Thailand showing significantly faster clinical improvement with favipiravir treatment. 1800mg favipiravir bid day 1, 800mg bid 5-14 days until PCR-.
time to clinical improvement, 63.9% lower, HR 0.36, p < 0.001, treatment 62, control 31, inverted to make HR<1 favor treatment, primary outcome.
clinical improvement, 89.9% lower, OR 0.10, p < 0.001, treatment 62, control 31, inverted to make OR<1 favor treatment, logistic regression, day 14, RR approximated with OR.
risk of mild pneumonia, 42.9% lower, RR 0.57, p = 0.25, treatment 8 of 62 (12.9%), control 7 of 31 (22.6%), NNT 10.
risk of no viral clearance, 4.2% higher, HR 1.04, p = 0.87, treatment 62, control 31, adjusted per study, inverted to make HR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sirijatuphat et al., 8 Jun 2022, Randomized Controlled Trial, Thailand, peer-reviewed, 9 authors, study period December 2020 - July 2021, trial TCTR20200514001.
This PaperFavipiravirAll
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Rujipas Sirijatuphat, Weerawat Manosuthi, Suvimol Niyomnaitham, Andrew Owen, Katherine K Copeland, Lantharita Charoenpong, Manoch Rattanasompattikul, Surakameth Mahasirimongkol, MD Kulkanya Chokephaibulkit
doi:10.1101/2022.06.06.22275902
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled (2:1) within 10 days of symptomatic onset into FPV and control arms. The former received 1800 mg FPV twice-daily (BID) on Day 1 and 800 mg BID 5-14 days thereafter until negative viral detection, while the latter received supportive care only. The primary endpoint was time to clinical improvement, which was defined by a reduced National Early Warning Score (NEWS) or score of <1. 62 patients (41 female) comprised the FPV arm (median age: 32 years, median BMI: 22 kg/m²) and 31 patients (19 female) comprised the control arm (median age: 28 years, median BMI: 22 kg/m². The median time to sustained clinical improvement by NEWS was 2 vs 14 days for FPV and control arms respectively (adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88, P <0.001). The FPV arm also had significantly higher likelihoods of clinical improvement within 14 days after enrolment by NEWS (79% vs 32% respectively, P <0.001), particularly female patients (aOR 6.35, 95% CI 1.49-27.07, P <0.001). 8 (12.9%) and 7 (22.6%) patients in FPV and control arms developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after treatment, respectively (P = 0.316); all recovered well without complications. We can conclude that early treatment of FPV in symptomatic COVID-19 patients without pneumonia was associated with faster clinical improvement.
Declaration of Interest Statement AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO
References
Ader, Bouscambert-Duchamp, Hites, Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, Lancet Infect Dis
Agrawal, Raju, Udwadia, Favipiravir: A new and emerging antiviral option in COVID-19, Med J Armed Forces India
Alene, Yismaw, Assemie, Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis, PLoS One
Bai, Mu, Kargbo, Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014, Clin Infect Dis
Baranovich, Wong, Armstrong, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J Virol
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, New England Journal of Medicine
Brophy, Molnupiravir's authorisation was premature
Cai, Yang, Liu, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Chen, Chao, Lai, Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients, J Infect
Chuah, Chow, Hor, Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial, Clin Infect Dis
Deng, Yang, Yang, Evaluation of favipiravir in the treatment of COVID-19 based on the real-world, Expert Rev Anti Infect Ther
Do, National Early Warning Score, National Clinical Guideline
Doi, Hibino, Hase, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob Agents Chemother
Eroglu, Toprak, Overview of favipiravir and remdesivir treatment for COVID-19
Fischer, Eron, Holman, A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Fujifilm Toyama, Co, Notice of The New Drug Application Approval of "AVIGAN® Tablet 200mg
Fujii, Ibe, Ishigo, Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients, Journal of Infection and Chemotherapy
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci
Ghasemnejad-Berenji, Pashapour, Favipiravir and COVID-19: A Simplified Summary, Drug Res (Stuttg)
Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
Gowen, Wong, Jung, In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections, Antimicrob Agents Chemother
Hassanipour, Arab-Zozani, Amani, The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep
Holubar, Subramanian, Purington, Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial, Clin Infect Dis
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Kelleni, Tocilizumab, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment, SN Compr Clin Med
Ko, Jeon, Ryu, Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells, J Med Virol
Kumari, Rawat, Saha, Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update, Curr Pharmacol Rep
Kutsuna, Coronavirus disease
Lu, Chen, Lee, Potential therapeutic agents against COVID-19: What we know so far, J Chin Med Assoc
Manabe, Kambayashi, Akatsu, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis
Manosuthi, Jeungsmarn, Okada, Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir, Jpn J Infect Dis
Mendenhall, Russell, Smee, Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever, PLoS Negl Trop Dis
Nalbandian, Sehgal, Gupta, Post-acute COVID-19 syndrome, Nat Med
Oestereich, Lüdtke, Wurr, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Organization, WHO Coronavirus (COVID-19) Dashboard
Pertinez, Rajoli, Khoo, Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2, J Antimicrob Chemother
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad
Pongpirul, Wiboonchutikul, Charoenpong, Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand, PLoS Negl Trop Dis
Prakash, Singh, Kaur, Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients, Indian J Pharmacol
Prasithsirikul, Pongpirul, Sakornsakolpat, Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand, Asian Biomedicine
Reddy, Lai, Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options, Chembiochem
Sawanpanyalert, Sirijatuphat, Sangsayunh, Assessement of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand, Southeast Asian Journal of Tropical Medicine and Public Health
Seneviratne, Abeysuriya, Mel, Favipiravir in COVID-19, International Journal of Progressive Sciences and Technologies
Sheahan, Sims, Zhou, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med
Shinada, Sato, Moriyama, Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir, Viruses
Shrestha, Budhathoki, Khadka, Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J
Siemieniuk, Bartoszko, Ge, Drug treatments for covid-19: living systematic review and network meta-analysis, Bmj
Srinivas, Sacha, Koval, Antivirals for COVID-19, Cleaveland Clinical Journal of Medicine
Thorlund, Sheldrick, Mills, Molnupiravir for Covid-19 in Nonhospitalized Patients
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNAdependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wei, Moradkhani, Hezaveh, Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis International Journal of Scientific Research in Dental, and Medical Sciences
Yanai, Favipiravir: A Possible Pharmaceutical Treatment for COVID-19, Journal of Endocrinology & Metabolism
Özlüşen, Kozan, Akcan, Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis
{ 'DOI': '10.1101/2022.06.06.22275902', 'URL': 'http://dx.doi.org/10.1101/2022.06.06.22275902', 'abstract': '<jats:title>Abstract</jats:title><jats:p>We investigated Favipiravir (FPV) efficacy in mild ' 'cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical ' 'condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected ' 'patients without pneumonia were enrolled (2:1) within 10 days of symptomatic onset into FPV ' 'and control arms. The former received 1800 mg FPV twice-daily (BID) on Day 1 and 800 mg BID ' '5-14 days thereafter until negative viral detection, while the latter received supportive ' 'care only. The primary endpoint was time to clinical improvement, which was defined by a ' 'reduced National Early Warning Score (NEWS) or score of ≤1. 62 patients (41 female) comprised ' 'the FPV arm (median age: 32 years, median BMI: 22 kg/m²) and 31 patients (19 female) ' 'comprised the control arm (median age: 28 years, median BMI: 22 kg/m². The median time to ' 'sustained clinical improvement by NEWS was 2 vs 14 days for FPV and control arms respectively ' '(adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88, <jats:italic>P</jats:italic> ' '&lt;0.001). The FPV arm also had significantly higher likelihoods of clinical improvement ' 'within 14 days after enrolment by NEWS (79% vs 32% respectively, <jats:italic>P</jats:italic> ' '&lt;0.001), particularly female patients (aOR 6.35, 95% CI 1.49-27.07, ' '<jats:italic>P</jats:italic> &lt;0.001). 8 (12.9%) and 7 (22.6%) patients in FPV and control ' 'arms developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after ' 'treatment, respectively (<jats:italic>P</jats:italic> = 0.316); all recovered well without ' 'complications. We can conclude that early treatment of FPV in symptomatic COVID-19 patients ' 'without pneumonia was associated with faster clinical improvement.</jats:p>', 'accepted': {'date-parts': [[2022, 6, 8]]}, 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-1486-5550', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Sirijatuphat', 'given': 'Rujipas', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0003-2583-9390', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Manosuthi', 'given': 'Weerawat', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4785-2716', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Niyomnaitham', 'given': 'Suvimol', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Owen', 'given': 'Andrew', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Copeland', 'given': 'Katherine K.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-3811-0267', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Charoenpong', 'given': 'Lantharita', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-1150-2597', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Rattanasompattikul', 'given': 'Manoch', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-7555-1056', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Mahasirimongkol', 'given': 'Surakameth', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-0140-4600', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Chokephaibulkit', 'given': 'Kulkanya', 'sequence': 'additional'}], 'container-title': [], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 6, 8]], 'date-time': '2022-06-08T15:00:11Z', 'timestamp': 1654700411000}, 'deposited': { 'date-parts': [[2022, 6, 10]], 'date-time': '2022-06-10T09:46:15Z', 'timestamp': 1654854375000}, 'group-title': 'Pharmacology and Therapeutics', 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T04:35:24Z', 'timestamp': 1711600524335}, 'institution': [{'name': 'medRxiv'}], 'is-referenced-by-count': 1, 'issued': {'date-parts': [[2022, 6, 8]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.06.06.22275902', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '246', 'original-title': [], 'posted': {'date-parts': [[2022, 6, 8]]}, 'prefix': '10.1101', 'published': {'date-parts': [[2022, 6, 8]]}, 'publisher': 'Cold Spring Harbor Laboratory', 'reference': [ { 'key': '2022061002451014000_2022.06.06.22275902v1.1', 'unstructured': 'Organization WH. WHO Coronavirus (COVID-19) Dashboard 2022. Available ' 'from: https://covid19.who.int/'}, { 'DOI': '10.35772/ghm.2020.01031', 'article-title': 'Coronavirus disease 2019 (COVID-19): research progress and clinical ' 'practice', 'doi-asserted-by': 'crossref', 'first-page': '78', 'issue': '2', 'journal-title': 'Glob Health Med', 'key': '2022061002451014000_2022.06.06.22275902v1.2', 'volume': '2', 'year': '2020'}, { 'DOI': '10.1016/j.jinf.2021.01.015', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.3'}, { 'article-title': 'Experimental Treatment with Favipiravir for COVID-19: An Open-Label ' 'Control Study', 'first-page': '1192', 'issue': '10', 'journal-title': 'Engineering (Beijing)', 'key': '2022061002451014000_2022.06.06.22275902v1.4', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1371/journal.pntd.0008806', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.5'}, { 'DOI': '10.1016/j.ijid.2020.10.069', 'article-title': 'Role of favipiravir in the treatment of COVID-19', 'doi-asserted-by': 'crossref', 'first-page': '501', 'journal-title': 'Int J Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.6', 'volume': '102', 'year': '2021'}, { 'DOI': '10.1371/journal.pone.0249090', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.7'}, { 'DOI': '10.1128/AAC.01897-20', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.8', 'unstructured': 'Doi Y , Hibino M , Hase R , et al. A Prospective, Randomized, Open-Label ' 'Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients ' 'with COVID-19. Antimicrob Agents Chemother. 2020 Nov 17;64(12).'}, { 'DOI': '10.1016/j.ijid.2020.11.142', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.9'}, { 'DOI': '10.1038/s41591-021-01283-z', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.10'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.11', 'unstructured': 'Eroglu E , Toprak C. Overview of favipiravir and remdesivir treatment ' 'for COVID-19. International Journal of Pharmaceutical Sciences and ' 'Research. 2021:1950–1957.'}, { 'DOI': '10.1007/s40495-020-00226-5', 'article-title': 'Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 ' 'Pandemic: a Recent Update', 'doi-asserted-by': 'crossref', 'first-page': '228', 'issue': '5', 'journal-title': 'Curr Pharmacol Rep', 'key': '2022061002451014000_2022.06.06.22275902v1.12', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1186/s12879-021-06164-x', 'article-title': 'Favipiravir for the treatment of patients with COVID-19: a systematic ' 'review and meta-analysis', 'doi-asserted-by': 'crossref', 'first-page': '489', 'issue': '1', 'journal-title': 'BMC Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.13', 'volume': '21', 'year': '2021'}, { 'article-title': 'Evaluating the Treatment with Favipiravir in Patients Infected by ' 'COVID-19', 'first-page': '87', 'issue': '3', 'journal-title': 'A Systematic Review and Meta-analysis International Journal of ' 'Scientific Research in Dental and Medical Sciences', 'key': '2022061002451014000_2022.06.06.22275902v1.14', 'volume': '2', 'year': '2020'}, { 'DOI': '10.1007/s42399-021-00824-4', 'article-title': 'Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for ' 'COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment', 'doi-asserted-by': 'crossref', 'first-page': '919', 'issue': '4', 'journal-title': 'SN Compr Clin Med', 'key': '2022061002451014000_2022.06.06.22275902v1.15', 'volume': '3', 'year': '2021'}, { 'DOI': '10.1002/jmv.26397', 'article-title': 'Comparative analysis of antiviral efficacy of FDA-approved drugs ' 'against SARS-CoV-2 in human lung cells', 'doi-asserted-by': 'crossref', 'first-page': '1403', 'issue': '3', 'journal-title': 'J Med Virol', 'key': '2022061002451014000_2022.06.06.22275902v1.16', 'volume': '93', 'year': '2021'}, { 'DOI': '10.1002/cbic.202000595', 'article-title': 'Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic ' 'Options', 'doi-asserted-by': 'crossref', 'first-page': '939', 'issue': '6', 'journal-title': 'Chembiochem', 'key': '2022061002451014000_2022.06.06.22275902v1.17', 'volume': '22', 'year': '2021'}, { 'DOI': '10.1186/s12985-020-01412-z', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.18'}, { 'DOI': '10.1056/NEJMoa2116846', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.19'}, { 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'doi-asserted-by': 'crossref', 'first-page': '509', 'issue': '6', 'journal-title': 'New England Journal of Medicine', 'key': '2022061002451014000_2022.06.06.22275902v1.20', 'volume': '386', 'year': '2022'}, { 'DOI': '10.1056/NEJMc2201612', 'article-title': 'Molnupiravir for Covid-19 in Nonhospitalized Patients', 'doi-asserted-by': 'crossref', 'first-page': 'e32', 'issue': '13', 'journal-title': 'New England Journal of Medicine', 'key': '2022061002451014000_2022.06.06.22275902v1.21', 'volume': '386', 'year': '2022'}, { 'DOI': '10.1136/bmj.o443', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.22', 'unstructured': 'Brophy JM . Molnupiravir’s authorisation was premature. British Medical ' 'Journal Publishing Group; 2022.'}, { 'article-title': 'Favipiravir in COVID-19', 'first-page': '143', 'issue': '2', 'journal-title': 'International Journal of Progressive Sciences and Technologies', 'key': '2022061002451014000_2022.06.06.22275902v1.23', 'volume': '19', 'year': '2020'}, { 'DOI': '10.2183/pjab.93.027', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.24'}, { 'DOI': '10.1016/j.mjafi.2020.08.004', 'article-title': 'Favipiravir: A new and emerging antiviral option in COVID-19', 'doi-asserted-by': 'crossref', 'first-page': '370', 'issue': '4', 'journal-title': 'Med J Armed Forces India', 'key': '2022061002451014000_2022.06.06.22275902v1.25', 'volume': '76', 'year': '2020'}, { 'DOI': '10.1038/s41422-020-0282-0', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.26'}, { 'DOI': '10.1093/cid/ciaa1176', 'article-title': 'AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease ' '2019 (COVID-19): Interim Results of a Phase II/III Multicenter ' 'Randomized Clinical Trial', 'doi-asserted-by': 'crossref', 'first-page': '531', 'issue': '3', 'journal-title': 'Clin Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.27', 'volume': '73', 'year': '2021'}, { 'DOI': '10.14740/jem645', 'article-title': 'Favipiravir: A Possible Pharmaceutical Treatment for COVID-19', 'doi-asserted-by': 'crossref', 'first-page': '33', 'issue': '2', 'journal-title': 'Journal of Endocrinology & Metabolism', 'key': '2022061002451014000_2022.06.06.22275902v1.28', 'volume': '10', 'year': '2020'}, { 'DOI': '10.1093/cid/ciac312', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.29', 'unstructured': 'Holubar M , Subramanian A , Purington N , et al. Favipiravir for ' 'treatment of outpatients with asymptomatic or uncomplicated COVID-19: a ' 'double-blind randomized, placebo-controlled, phase 2 trial. Clin Infect ' 'Dis. 2022 Apr 21.'}, { 'DOI': '10.3390/v14040670', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.30', 'unstructured': 'Shinada K , Sato T , Moriyama S , et al. Longitudinal Analysis of ' 'Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after ' 'Treatment with or without Favipiravir. Viruses. 2022 Mar 24;14(4).'}, { 'DOI': '10.1007/s10096-021-04307-1', 'article-title': 'Effectiveness of favipiravir in COVID-19: a live systematic review', 'doi-asserted-by': 'crossref', 'first-page': '2575', 'issue': '12', 'journal-title': 'Eur J Clin Microbiol Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.31', 'volume': '40', 'year': '2021'}, { 'DOI': '10.1136/bmj.m2980', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.32'}, { 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'The efficacy and safety of Favipiravir in treatment of COVID-19: a ' 'systematic review and meta-analysis of clinical trials', 'doi-asserted-by': 'crossref', 'first-page': '11022', 'issue': '1', 'journal-title': 'Sci Rep', 'key': '2022061002451014000_2022.06.06.22275902v1.33', 'volume': '11', 'year': '2021'}, { 'DOI': '10.1016/S2055-6640(20)30016-9', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.34'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.35', 'unstructured': 'Fujifilm Toyama Chemical Co. L. Notice of The New Drug Application ' 'Approval of “AVIGAN® Tablet 200mg” in Japan for the Anti-influenza Virus ' 'Drug 2014. Available from: ' 'https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw'}, { 'DOI': '10.1515/abm-2020-0016', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.36', 'unstructured': 'Prasithsirikul W , Pongpirul K , Sakornsakolpat P , et al. Adjunctive ' 'favipiravir for severe COVID-19: a retrospective observational study of ' 'the first 41 patients in Thailand. Asian Biomedicine. 2020;14(3).'}, { 'DOI': '10.1371/journal.pntd.0001342', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.37'}, { 'DOI': '10.1016/j.antiviral.2014.02.014', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.38'}, { 'DOI': '10.1128/AAC.00356-07', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.39'}, { 'DOI': '10.1093/cid/ciw571', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.40'}, { 'DOI': '10.1097/JCMA.0000000000000318', 'article-title': 'Potential therapeutic agents against COVID-19: What we know so far', 'doi-asserted-by': 'crossref', 'first-page': '534', 'issue': '6', 'journal-title': 'J Chin Med Assoc', 'key': '2022061002451014000_2022.06.06.22275902v1.41', 'volume': '83', 'year': '2020'}, { 'DOI': '10.1128/JVI.02346-12', 'doi-asserted-by': 'publisher', 'key': '2022061002451014000_2022.06.06.22275902v1.42'}, { 'DOI': '10.1126/scitranslmed.abb5883', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.43', 'unstructured': 'Sheahan TP , Sims AC , Zhou S , et al. An orally bioavailable ' 'broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial ' 'cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 ' 'Apr 29;12(541).'}, { 'article-title': 'Assessement of outcomes following implementation of antiviral treatment ' 'guidelines for COVID-19 during the first wave in Thailand', 'first-page': '572', 'issue': '4', 'journal-title': 'Southeast Asian Journal of Tropical Medicine and Public Health', 'key': '2022061002451014000_2022.06.06.22275902v1.44', 'volume': '52', 'year': '2021'}, { 'DOI': '10.1016/j.jiac.2021.04.013', 'article-title': 'Early favipiravir treatment was associated with early defervescence in ' 'non-severe COVID-19 patients', 'doi-asserted-by': 'crossref', 'first-page': '1051', 'issue': '7', 'journal-title': 'Journal of Infection and Chemotherapy', 'key': '2022061002451014000_2022.06.06.22275902v1.45', 'volume': '27', 'year': '2021'}, { 'DOI': '10.1055/a-1296-7935', 'article-title': 'Favipiravir and COVID-19: A Simplified Summary', 'doi-asserted-by': 'crossref', 'first-page': '166', 'issue': '3', 'journal-title': 'Drug Res (Stuttg)', 'key': '2022061002451014000_2022.06.06.22275902v1.46', 'volume': '71', 'year': '2021'}, { 'DOI': '10.3949/ccjm.87a.ccc030', 'doi-asserted-by': 'crossref', 'key': '2022061002451014000_2022.06.06.22275902v1.47', 'unstructured': 'Srinivas P , Sacha G , Koval C. Antivirals for COVID-19. Cleaveland ' 'Clinical Journal of Medicine. 2020.'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.48', 'unstructured': 'Medical Research Foundation T. Thai Clinical Trials Registry 2021. ' 'Available from: https://thaiclinicaltrials.org/'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.49', 'unstructured': 'Health Do. National Early Warning Score: National Clinical Guideline No. ' '1 2013.'}, { 'DOI': '10.4103/ijp.ijp_998_20', 'article-title': 'Systematic review and meta-analysis of effectiveness and safety of ' 'favipiravir in the management of novel coronavirus (COVID-19) patients', 'doi-asserted-by': 'crossref', 'first-page': '414', 'issue': '5', 'journal-title': 'Indian J Pharmacol', 'key': '2022061002451014000_2022.06.06.22275902v1.50', 'volume': '52', 'year': '2020'}, { 'DOI': '10.7883/yoken.JJID.2020.827', 'article-title': 'Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients ' 'Receiving Favipiravir', 'doi-asserted-by': 'crossref', 'first-page': '416', 'issue': '5', 'journal-title': 'Jpn J Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.51', 'volume': '74', 'year': '2021'}, { 'DOI': '10.1080/14787210.2022.2012155', 'article-title': 'Evaluation of favipiravir in the treatment of COVID-19 based on the ' 'real-world', 'doi-asserted-by': 'crossref', 'first-page': '555', 'issue': '4', 'journal-title': 'Expert Rev Anti Infect Ther', 'key': '2022061002451014000_2022.06.06.22275902v1.52', 'volume': '20', 'year': '2022'}, { 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'doi-asserted-by': 'crossref', 'first-page': 'eabl7430', 'issue': '628', 'journal-title': 'Sci Transl Med', 'key': '2022061002451014000_2022.06.06.22275902v1.53', 'volume': '14', 'year': '2022'}, { 'DOI': '10.1016/S1473-3099(21)00485-0', 'article-title': 'Remdesivir plus standard of care versus standard of care alone for the ' 'treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a ' 'phase 3, randomised, controlled, open-label trial', 'doi-asserted-by': 'crossref', 'first-page': '209', 'issue': '2', 'journal-title': 'Lancet Infect Dis', 'key': '2022061002451014000_2022.06.06.22275902v1.54', 'volume': '22', 'year': '2022'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.55', 'unstructured': 'Chuah CH , Chow TS , Hor CP , et al. Efficacy of Early Treatment with ' 'Favipiravir on Disease Progression among High Risk COVID-19 Patients: A ' 'Randomized, Open-Label Clinical Trial. Clin Infect Dis. 2021 Nov 19.'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.56', 'unstructured': '35 generic manufacturers sign agreements with MPP to produce low-cost, ' 'generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in ' 'combination with ritonavir for supply in 95 low-and middle-income ' 'countries [Internet]. Medicines Patent Pool; 2022. Available from: ' 'https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.57', 'unstructured': '27 generic manufacturers sign agreements with MPP to produce low-cost ' 'versions of COVID-19 antiviral medication molnupiravir for supply in 105 ' 'low-and-middle-income countries [Internet]. Medicines Patent Pool; 2022. ' 'Available from: ' 'https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir'}, { 'DOI': '10.1093/jac/dkab135', 'article-title': 'Pharmacokinetic modelling to estimate intracellular favipiravir ' 'ribofuranosyl-5’-triphosphate exposure to support posology for ' 'SARS-CoV-2', 'doi-asserted-by': 'crossref', 'first-page': '2121', 'issue': '8', 'journal-title': 'J Antimicrob Chemother', 'key': '2022061002451014000_2022.06.06.22275902v1.58', 'volume': '76', 'year': '2021'}], 'reference-count': 58, 'references-count': 58, 'relation': {}, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2022.06.06.22275902'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'subtype': 'preprint', 'title': 'Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, ' 'Open-Labelled, Randomized Control Study', 'type': 'posted-content'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit